{"entity":{"id":"isciii","kind":"institution","name":"Instituto de Salud Carlos III (ISCIII)","aka":["ISCIII","Carlos III Health Institute"],"tldr":"Spain's public health research institute. It created the CIBER research networks, including the cancer network CIBERONC, and funds academic trials such as Barcelona's CAR-T studies.","summary":"The Instituto de Salud Carlos III is Spain's public biomedical and health research body. The CIBER consortium describes itself as a public research consortium created on the initiative of the ISCIII, dating from 2006, and it added cancer as a thematic area, CIBERONC, on 1 January 2017. The ISCIII is listed on ClinicalTrials.gov as a collaborator on CART19-BE-01, the trial behind the academic CAR-T ARI-0001, and is named first among the funders of CARTBCMA-HCB-01, the trial of the academic BCMA CAR-T ARI0002h.\n\nThe ISCIII's own website returned a maintenance page on 3 November 2026, so this record does not describe its budget, its centres or its funding calls; those are named as a gap on the Spain page.","asOf":"2026-11-03","links":[{"label":"CIBER: quiénes somos","url":"https://www.ciberisciii.es/quienes-somos"},{"label":"ClinicalTrials.gov NCT03144583","url":"https://clinicaltrials.gov/study/NCT03144583"},{"label":"CARTBCMA-HCB-01, Lancet Oncol 2023 (funding statement)","url":"https://doi.org/10.1016/S1470-2045(23)00222-X"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ciberonc","cnio"],"pathways":[],"terms":[],"trials":["cart19-be-01","cartbcma-hcb-01"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.478,"lng":-3.708,"institutionType":"government","website":"https://www.isciii.es","programs":["CIBER consortium (including CIBERONC)","Health research funding (Acción Estratégica en Salud)"]},"route":"/institutions/isciii/","neighbours":{"institution":[{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/"},{"id":"ciberonc","kind":"institution","name":"CIBERONC (Centro de Investigación Biomédica en Red de Cáncer)","route":"/institutions/ciberonc/"},{"id":"redecan","kind":"institution","name":"Spanish Network of Cancer Registries (REDECAN)","route":"/institutions/redecan/"}],"trial":[{"id":"cart19-be-01","kind":"trial","name":"CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cart19-be-01/"},{"id":"cartbcma-hcb-01","kind":"trial","name":"CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cartbcma-hcb-01/"}],"paper":[{"id":"paper-cartbcma-hcb-01-lancet-oncol-2023","kind":"paper","name":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","route":"/key-papers/paper-cartbcma-hcb-01-lancet-oncol-2023/"}]}}